Form 4: SOPHIA GENETICS SA: Insider Sells Shares for Tax Withholding

Daan van Well, Chief Legal Officer of SOPHiA GENETICS SA, sold 684 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

Summary

• Daan van Well, Chief Legal Officer of SOPHiA GENETICS SA, reported a transaction on May 19, 2026.
• The transaction involved the sale of 684 ordinary shares.
• These shares were sold to satisfy tax withholding obligations due to the vesting of restricted stock units on May 18, 2026.
• The sales were conducted under a pre-established Rule 10b5-1(c) trading plan, indicating they were not discretionary.
• The shares were sold at a weighted average price of $4.6042, with individual sale prices ranging from $4.54 to $4.66.
• Following the transaction, Mr. van Well beneficially owns 345,052 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; the sale is routine for tax purposes and executed under a compliant trading plan, not indicative of a negative view on the company's prospects.

Positives

• The sale was executed under a Rule 10b5-1(c) trading plan, which is designed to comply with insider trading regulations and provides an affirmative defense against allegations of insider trading.
• The transaction was for tax withholding purposes, a common and expected event for executives receiving equity compensation.
• The reporting person retains a significant beneficial ownership of 345,052 ordinary shares.

Negatives

• The sale represents a reduction in the reporting person's direct shareholding, although it was for a specific, non-discretionary purpose.

Risks

• While the sale was part of a pre-planned trading strategy for tax purposes, any significant insider selling can be perceived negatively by the market.
• The weighted average sale price of $4.6042 may indicate the current market valuation of the shares at the time of the transaction.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing, as it solely reports a completed transaction.

Management Comments

• Sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine for publicly traded companies and are used to report changes in beneficial ownership by insiders. The use of a Rule 10b5-1(c) trading plan, as indicated here, is a standard practice for executives to manage equity sales in a compliant manner, particularly for covering tax liabilities.

Stakeholder Impact

• Shareholders: The sale is a minor event and unlikely to significantly impact share price due to its planned nature and tax-related purpose. However, any insider selling can be a point of observation.
• Employees: No direct impact on employees is indicated by this transaction.
• Management: This is a standard operational event for executive compensation management.

Next Steps

• The reporting person may continue to execute trades under the Rule 10b5-1(c) plan if it remains active.
• The company may receive requests for detailed pricing information regarding the sales.

Key Dates

Keywords

SOPHiA GENETICS SA, SOPH, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Tax Withholding, Restricted Stock Units, Beneficial Ownership, Chief Legal Officer